Upload
rollo
View
37
Download
0
Embed Size (px)
DESCRIPTION
CORSO DI LAUREA SPECIALISTICA IN BIOTECNOLOGIE DEL FARMACO AA 2010-11 Adriana Maggi LEZIONE 13. INGEGNERIA ANIMALE APPLICAZIONI. I SISTEMI REPORTER POSSONO ESSERE UTILIZZATI PER LA GENERAZIONE DI ANIMALI IN CUI SI POSSANO MISURARE EVENTI MOLECOLARI SPECIFICI IN TEMPO REALE?. - PowerPoint PPT Presentation
Citation preview
INGEGNERIA ANIMALEAPPLICAZIONI
CORSO DI LAUREA SPECIALISTICA IN BIOTECNOLOGIE DEL FARMACO AA 2010-11
Adriana MaggiLEZIONE 13
I SISTEMI REPORTER POSSONO ESSERE UTILIZZATI PER LA GENERAZIONE DI ANIMALI IN CUI SI POSSANO MISURARE EVENTI MOLECOLARI SPECIFICI IN TEMPO REALE?
IN VIVO IMAGING
MULTI-MODALITY MOLECULAR IMAGING IN LIVING SMALL ANIMALS
Functional Magnetic Nuclear Resonance
Optical imagingBioluminescence
Ultrasound
MicroPETPositron emission tomography
Nuclear imaging
Micro SPECTsingle-photon emission
computerized tomography
2/06
Fluorescence
LA GENERAZIONE DI UN TOPO REPORTER
La scelta del:
sistema di ingegneria animale
reporter bioluminescenza, PET, NMR
costrutto
reporter
Reporter bioluminescenti e fluorescenti
I geni reporter
Monomerico, non richiede substrato, assente nei mammiferi, varianti con diversa l di fluorescenza. Bassa sensibilità per mancanza di amplificazione
fluorescent proteins (GFP, varianti RFP, BFP)
Utilizzabili per PETDifficoltà nel generare i ligandi radiomarcati
Ligandi per sostanze radiomarcate
Alta attività specifica, mancanza di attività endogena (basso bkg) Richiede l’aggiunta di cofattore, O2, ATP.
Luciferasi (Lucciola)
Utile per studi di tipo anatomico-funzionale
Ben caratterizzata, stabile, rilevazione automatizzabile
B-Galattosidasi (Batterica)
GENE
Presenza di attività endogena in cellule di mammifero, enzima tetramerico (risposta non lineare)
Applicabile a studi di bioluminescenza in vivo
Applicabile a studi di fluorescenza in vivo
LA GENERAZIONE DI UN TOPO REPORTER
La scelta del:
sistema di ingegneria animale
reporter bioluminescenza, PET, NMR
costrutto
reporter
Studio della funzione di promotore
reporter gene reporter gene
I sistemi reporter nello studio di rilascio/sintesi di trasduttori del segnale (complementazione)
I sistemi reporter nello studio di interazioni tra proteine
INSULATOR( MAR )
INSULATOR
( MAR )
lightluciferin + ATP = oxyluciferin + AMP +
TKERE 2x
firefly luciferase
+/- +/-
ERE-Luc reporter mouse
The ERE-Luc reporter mouse: a model to study of ER transcriptional activity
Ciana et al., 2001
ERE
kinase-dependent activation
i.p. of D-luciferin
20 min.
Evaluation of ER transcriptional activity
5 min. after the acquisition
18.516.514.513.5 15.5
ERE-Luc mouse
ER is transcriptionally active at day 14.5 pc
dpc (day post conception)
ERE-Luc mouse
P118.516.514.513.512.5dpc (day post conception) post-natal
day 1
endoderm mesoderm ectodermimaging IHC
A B C D
E
F
G
H
C – intestine 20xD – bone 40xE – heart 40xF – forebrain 10xG – moustache 40x H – skin 20x
16.5 dpc 16.5 dpc
GP Rando, 2007
ERE-Luc mouse bone
0
2
4
6
thymus
01
23
4
brain
0
5
10
15
20
P E M D2
intestine
0
48
1216
bone
0
2
4
6
thymus
01
23
4
brain
0
5
10
15
20
LUCI
FERA
SE A
CTIV
ITY
(RLU
)
P E D
intestine
0
48
1216
liver
0
10
20
P E M D2
ovaries
0
2
4
uterus
13579
0
6
12
liver
0
10
20
P E D2P E D
ovaries
0
2
4
uterus
13579
0
6
12 hypothalamus
M D P E
Estr
adio
l(pg/m
l)
1020
30
40
50
day 1 day 2 day3 day 4
SESTRUS
E2
(p
g/m
l)
1020304050
M D P E
Luciferase activity in adult, cycling females
Ciana et al, Nature Ned., 2003
Suckling Mice
Pregnancy &
EmbryoDevelopment
13.5
14.5
15.5
16.5
17.5
18.5
19.5
12.5
DAY 18.5
DAY 16.5
DAY 13.5
DAY 14.5
DAY 15.5
DAY 1
DAY 10
Immature Mice
Adult Mice
LIFE
CYCLE
ERE-Luc mice to understand ER involvement in mammals physiopathology
THE COMPLEXITY OFESTROGEN ACTION
ERE
G-protein,
IP3K...
SP1NFKBAP1
THE COMPLEXITY OF ESTROGEN TARGETS
• REPRODUCTIVE SYSTEM- male and female gonads- hypothalamus and pituitary
• SKELETAL SYSTEM• VASCULAR SYSTEM
- endothelium- smooth muscle cells
• RESPIRATORY SYSTEM• IMMUNE SYSTEM• NERVOUS SYSTEM
- central- peripheral
CNS
cardiovascular
reproductive
bone
ERE
SP1NFKBAP1
tissue-specificcoregulators
growthfactors P
ER COMPLEXITY OF ACTION and A NEW CLASS OF DRUGS: Selective Estrogen Recepor Modulators
ESTROGEN REPLACEMENT THERAPY
The efficacy of SERMs on estrogen receptor transcriptional activity was measured in a model
of surgical menopause (ovx mice)
SERMs ability to replace the natural hormone was evaluated by comparison with ER activity in
healthy, cycling mice
Reproductive organs(mammari glands and vagina)
Muscle-Skeletal System
Hepatic area
Measuring bioluminscence in the ERE-Luc reporter mouse
Thymic area
Intestine
Bioluminescence after6h treatment with
15b-estradiol (50ug/kg)
pellet days of treatment
CONTROLS
REFERENCE DRUG
DRUG OF INTEREST
Manual
In vivo analysis of photon emission
Automatic
Rando et al. 2009
REPORTER MICE TO STUDY DRUG ACTION “IN VIVO”
0
5
10
15
20 UTERUS
RLU
0
500000
1000000
1500000
2000000
AUC
VAGINA
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2110000
40000
70000
100000
VAGINA
Days
Phot
on e
miss
ion
p/s/
cm2/
sr
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 210
100000
200000
300000
400000
CHEST
Days
Phot
on
emis
sion
p/
s/cm
2/sr
0
2000000
4000000
6000000
8000000
AUC
CHEST
0
100
200
300
400
500 LIVER
RLU
VehiclePCUD 3mg/kgBZA 10mg/kgBZA 10mg/kg + PCUD 3mg/kgRaloxifene 10mg/kg
Luciferase enzymatic activityPhoton emission
Biserni et al, in preparation
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2110000
40000
70000
100000
REPRODUCTIVE AREA
Days
Phot
on e
mis
sion
p/
s/cm
2/sr
0
500000
1000000
1500000
2000000
AUC
°**
VehiclePCUD 3mg/kgBZA 10mg/kgBZA 10mg/kg + PCUD 3mg/kgRaloxifene 10mg/kg
Effects of SERMs on ER activity – in vivo imaging
CHRONIC treatment (21 days)
Biserni et al, in preparation
Effects of SERMs on ER activity – in vivo imaging
CHRONIC treatment (21 days)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2120000
40000
60000
80000
100000
TAIL
Days
Phot
on e
mis
sion
p/
s/cm
2/sr
0
500000
1000000
1500000
2000000
AUC
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2120000
40000
60000
80000
100000
LIMBS
Days
Phot
on e
mis
sion
p/
s/cm
2/sr
0
500000
1000000
1500000
2000000
AUC
VehiclePCUD 3mg/kgBZA 10mg/kgBZA 10mg/kg + PCUD 3mg/kgRaloxifene 10mg/kg
Biserni et al, in preparation
limb
0
100
200
300
400
500
AU
C
tail
0
50
100
150
200
250
AU
C
limb
0
50
100
150
200
250
cts/c
m2 s
(vs c
yc=
100%
)
tail
0
50
100
150
200300400500600
cts
/cm2 s
(vs c
yc=
100%
)
LIMB TAIL
ACUTE
CHRONIC
ovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAMovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAM
Rando et al, Mol. Endocrinol. 2010
hepatic
0
100
200
300
500150025003500
AU
C
abdomen
0
50
100
150
200
250
AU
C
hepatic
0
100
200
300
400500
100015002000
cts/c
m2 s
(vs
cy
c=
100
%)
abdomen
0
50
100
150
200
250
cts
/cm2 s
(vs c
yc=
100%
)
HEPATIC AREA ABDOMENACUTE
CHRONIC
ovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAMovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAM
Rando et al, Mol. Endocrinol. 2010
SERCHING FOR NOVEL MODALITIES TO MEASURE THE EFFICACY OF SERMs
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 210
100000
200000
300000
400000
CHEST
Days
Phot
on e
mis
sion
p/
s/cm
2/sr
AUC
N° peaks, amplitude, frequency
0
3
6
9
12
0
2
4
6
8
0
3
6
9
12
0
2
4
6
8
Peak
s/21
dPe
riod
(d)
GENITAL AREA SKELETAL AREA
***
*
*
* ****
2
3
4
5
6
2
3
4
5
6
Ampl
itude
0
50
100
150
200
250
0
100
200
300400600800
**
* ***
050
100150200300450600
0
50
100
150
200
***
*
**
D
A
B
C
E
AUC
Pote
ncy
ovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAMovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAM
Rando et al, Mol. Endocrinol. 2010
PHENETICS OF DRUG ACTION
THE APPLICATION OF AGGLOMERATIVE HIERARCHICAL CLUSTERING
(AGGLOMERATIVE NESTING version 1.02 )
2
4
6
8
0.1
1
10
100
1000
10
100
1000
10000
**p<0.01
0 2 4 6 81
10
100
2 4 6 8 0.1 1 10 100
**p<0.01
10 100 1000 10000
**p<0.01
peak number period amplitude AUC
per
iod
amp
litu
de
AU
Cp
ote
ncy
a
period 0.04
amplitude 0.05 <0.01
AUC 0.03 0.05 0.96
potency 0.10 0.05 0.76 0.46
peaks number
period amplitude AUC
b
DEGREE OF FUNCTIONAL CORRELATION AMONG THE PARAMETERS SELECTED
Rando et al, Mol. Endocrinol. 2010
Space-temporal analysis of drug action in living animals
clustering data to generate novel families of compounds
Genital area
Skeletal area
ovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAMovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAMRando et al, Mol. Endocrinol. 2010
Genital area
Skeletal area
Reverse Medicinal ChemistryA
B
C
Cl
ovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAMovx cyc E2 CE CE+BZA BZA RAL10RAL2 LAS OSP TAM
Rando et al, Mol. Endocrinol. 2010
CONCLUSION 1
Adding the time dimension to the study of drug activity leads to a novel ability to define drug efficacy
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 220
2000
4000
6000
8000
LIMBGENITALAREAHEPATIC AREA
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 220
20000
40000
60000
80000
LIMBGENITAL AREAHEPATIC AREA
INTACT
OVX
Biserni et al. in preparation
TISSUE SPECIFIC EFFECT OF OVX ON THE AMPLITUDE AND FREQUENCY OF ER ACTIVITY
CONCLUSION 2
The possibility to measure in vivo the activity of estrogenic compounds on their target, may lead to the identification of novel and more efficacious therapies for the post-menopause
Funding: EU Strep EWA EWA LSHM-CT-2005-518245
EU IP CRESCENDO LSHM-CT-2005-018652
EU NoE DIMI LSHB-CT-2005-512146
NIH RO1(AG027713)
University of MilanCenter of Excellence on
Neurodegenerative Diseaseas
Collaborators at Milan University: Paola Campadelli
David Horner
Paolo CianaElisabetta Vegeto
Gianpaolo RandoValeria BenedusiSara Della TorreCristina VantaggiatoCristian IbarraBalaji RamachandranAndrea BiserniMonica RebecchiClara Meda
“The whole is more than the sum of its parts “Aristotle (384 BC – 322 BC)Methapysics
The real impact of molecular engineering on drug discovery
MODERN PHARMACOLOGY NEEDS TO REVISIT ANIMAL
MODELS